Loading…
Loading…
HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors' medications. In many cases, these presc.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company. Key Highlights HCXT-2001 is an investigational, clinical-stage, oral, macrocyclic peptide inhibitor of IL-23R with an extended half-life, offering a potentially differentiated approach to oral.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management acro.
BioNTech, Gilead to test drug combination in advanced breast cancer trial
Both of these ETFs look the part, but only one is truly the better buy for investors.
Gilead Sciences (GILD) concluded the recent trading session at $153.57, signifying a -1.88% move from its prior day's close.
CWA Asset Management Group LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 24.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 78,639 shares of the biopharmaceutical company's stock after acquiring an additional 15,240 shares